Trial Profile
Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs IMA 950 (Primary) ; Poly ICLC (Primary) ; Varlilumab (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- 23 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2030.
- 08 Jul 2021 Planned number of patients changed from 30 to 14.
- 08 Jul 2021 Status changed from recruiting to active, no longer recruiting.